Construction and evaluation of hyaluronic acid-based copolymers as a targeted chemotherapy drug carrier for cancer therapy

2020 ◽  
Vol 31 (30) ◽  
pp. 305702
Author(s):  
Yuting Tang ◽  
Minglong Chen ◽  
Qian Xie ◽  
Lu Li ◽  
Lei Zhu ◽  
...  
2009 ◽  
Vol 19 (24) ◽  
pp. 4102 ◽  
Author(s):  
Ki Young Choi ◽  
Kyung Hyun Min ◽  
Jin Hee Na ◽  
Kuiwon Choi ◽  
Kwangmeyung Kim ◽  
...  

2017 ◽  
Vol 17 (8) ◽  
pp. 5139-5146 ◽  
Author(s):  
Hongxia Peng ◽  
Jilin Hu ◽  
Chuanyue Hu ◽  
Tengyan Wu ◽  
Xiuying Tian

2018 ◽  
Vol 2018 ◽  
pp. 1-11
Author(s):  
Huiling Lv ◽  
Chao Wu ◽  
Xuan Liu ◽  
Andi Bai ◽  
Yue Cao ◽  
...  

In this study, we prepared PTX-loaded mesoporous hollow SnO2 nanofibers conjugated with folic acid (SFNFP) for liver cancer therapy. According to SEM and TEM characterization, SFNF showed a mesoporous hollow structure. The average outer diameter was 200 nm, and the wall thickness was 50 nm. The DSC and XRD study showed that PTX in the channels of nanofibers was present in an amorphous state. The in vitro release experiments demonstrated that SFNF could efficiently improve the dissolution rate of PTX. Both in vitro cell experiments and in vivo antitumor experiments showed that SFNFP could efficiently inhibit the growth of liver cancer cells. Therefore, SFNF is a promising targeting antitumor drug delivery carrier.


2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Minglong Chen ◽  
Wenqi Zhang ◽  
Kai Yuan ◽  
Mingxiang Bo ◽  
Bin Chen ◽  
...  

Chemotherapy is a powerful cancer treatment but suffers from poor biocompatibility and a lack of tumor targeting. Here, we developed a CD44-targeted polymeric nanocomplex by encapsulating 10-hydroxycamptothecin (HCPT) into hyaluronic acid nanoparticles (HANP) for targeted cancer therapy. In vitro, the HANP/HCPT showed improved cytotoxicity to five cancer cell lines including HT29, A549, MDA-MB-231, HepG2, and MDA-MB-435 versus free HCPT. After systemic administration into MDA-MB-231 breast cancer xenograft, tumor growth was significantly inhibited 5.25 ± 0.21 times in the HANP/HCPT treated group relative to the nontreated group. In addition, the treatment response was also accessed and confirmed by 18F-fluoro-2-deoxy-D-glucose ([18F] FDG) positron emission tomography (PET). The MDA-MB-231 tumors responded to HANP/HCPT 7 days after the first treatment, which benefits treatment strategy adjustment and personalization. No apparent systemic toxic effects were seen in mice treated with HANP/HCPT. In summary, the HANPs have great promise as a targeted drug carrier for cancer chemotherapy. Our HANP platform can also deliver other hydrophobic chemotherapy agents.


2015 ◽  
Vol 200 ◽  
pp. 158-166 ◽  
Author(s):  
Hwa Seung Han ◽  
Ki Young Choi ◽  
Hyewon Ko ◽  
Jueun Jeon ◽  
G. Saravanakumar ◽  
...  

2017 ◽  
Vol 164 ◽  
pp. 309-316 ◽  
Author(s):  
Jeongwook Lee ◽  
Ki Chun Yoo ◽  
Jaehyoung Ko ◽  
Bowon Yoo ◽  
Joohuei Shin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document